The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of ch 16 February 2024
Immuno-dermatology company Alys Pharmaceuticals has launched with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by heal 12 February 2024
American dermatology company Verrica Pharmaceuticals has filed a lawsuit against Canada’s Dormer Laboratories related to the active ingredient cantharidin. 5 February 2024
UK-based dermatology company SkinBioTherapeutics plc is to acquire the issued share capital of Dermatonics, a specialist in innovative topical and dermatologica 25 January 2024
Last month, the European Commission (EC) approved Ebglyss (lebrikizumab) for the treatment of adult and adolescent patients with moderate-to-severe atopic derma 21 December 2023
The rare disease unit of Italian drugmaker Chiesi has secured US approval for Filsuvez (birch triterpenes), a new treatment for people with junctional epidermol 20 December 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.